8/11/2022

speaker
Conference Operator

Good day, ladies and gentlemen. You are currently on hold for today's conference. We are awaiting additional participants and we'll start very shortly. Thank you for your patience and please continue to hold. Thank you. Good day and welcome to the Synthetic Biologics Second Quarter 2022 Earnings Call. Today's conference is being recorded, and at this time I'd like to turn the conference over to Chris Calabrese. Please go ahead, sir.

speaker
Chris Calabrese
Investor Relations, Synthetic Biologics

Thank you, Operator, and good morning, everyone. Welcome to the Synthetic Biologics 2022 Second Quarter Investor Conference Call. Leading the call today will be Steven Chalcross, Chief Executive and Chief Financial Officer of Synthetic Biologics. Dr. Manel Cascaio, General Director of Synthetic Biologics, European Subsidiary. Dr. Frank Tafaro, Chief Operating Officer. And Dr. Vince Wade, Chair, Head of Corporate and Product Development of Synthetic Biologics are also on the call and will be available to answer questions during the Q&A session. Synthetic Biologics issued a press release this morning which provided operational highlights and included the financial results for the second quarter ending June 30th, 2022. The press release can be found in the investor section of the company website at syntheticbiologics.com. Together with the quarterly report on form 10Q for the quarter ended June 30th, 2022. We plan to file today with the Securities and Exchange Commission or SEC. In addition to the phone line, this call is being streamed live via webcast, which will be archived on the company website, www.syntheticbiologics.com, for 90 days. During this call, certain forward-looking statements regarding synthetic biologics and BCN Biosciences' current expectations and projections about future events will be made. Generally, the forward-looking statements could be identified by terminology such as may, should, expects, anticipates, intends, plans, beliefs, estimates, and similar expressions. These statements are based upon current beliefs, expectations, and assumptions, and are subject to a number of risks and uncertainties, including those set forth in synthetic biologics filings with the SEC, many of which are difficult to predict. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. The information on this call is provided only as of the date of this call, and Synthetic Biologics undertakes no obligation to update any forward lifting statements contained on this conference call on account of new information, future events, or otherwise, except as required by law. With that, I'd like to turn the call over to Steve. Steve?

speaker
Steven Chalcross
Chief Executive Officer and Chief Financial Officer, Synthetic Biologics

Thank you, Chris. Good morning, and I appreciate everyone taking the time to join us on this call today. In the second quarter of 2022, we continue to execute on our plan to advance our exciting portfolio of clinical assets and to address a number of structural and administrative items that we believe are critical to our long-term success. Today, I will present an update on our progress as well as outline our priorities and path forward. Our team continues to advance our highly differentiated oncolytic adenovirus programs and we believe we are well positioned to lead the clinical path forward for oncolytic virus therapies. First, our VCN01 product has been administered to 76 patients to date, and we believe that there are very few, if any, competing programs that have dosed as many patients by systemic administration as we have. we've generated promising clinical data that gives us the confidence to advance our products into important planned clinical trials. Thirdly, our programs are led and advised by a world-class team of renowned scientists as evidenced by ongoing clinical collaborations and the formation of our SAB earlier this year to advance our oncology pipeline. Finally, Our strong cash position of approximately $53.5 million is expected to comfortably take us into the first quarter of 2024. This should enable us to deliver on a number of value-enhancing milestones before we need to raise additional capital. I am very proud of how we positioned our company for future growth as we continue to work diligently to advance the development of our pipelines. Our oncolytic adenovirus platform currently comprises our lead clinical stage drug candidate, VCN01, a systemically administered oncolytic adenovirus designed to break down the tumor stroma, and preclinical stage drug candidate, VCN11, the first candidate from the truly novel of human shield technology that is designed to protect systemically administered oncolytic viruses from the host immune system. The differentiating mechanisms of action of these two product candidates are intended to improve the anti-tumor effect of both oncolytic viruses and co-administered chemotherapies and or other immuno-oncology products. Importantly, degrading the stroma can also expose new tumor antigens, turning cold tumors hot and enabling a sustained anti-tumor response by the patient's own immune system. In parallel with VCN01 and VCN11, our CIN4, or ribaximase program, is progressing in a phase 1b2a clinical study of L-genetic hematopoietic cell transplant, or ACT, recipients for the prevention of acute graft-versus-host disease in bone marrow transplant patients. I would now like to provide an overview of our pipeline and walk you through key updates, starting with our lead oncology product. VCN01 is designed for intravenous, intratumoral, and intravitreal delivery. It is engineered to selectively replicate within the tumor and has the potential to remodel the tumor matrix and increase tumor immunogenity. As a reminder, VCN01 was granted orphan drug designation in 2011 by the European Medicines Agency for the treatment of pancreatic ductal adenocarcinoma, or PDAC, and also granted orphan drug designation by the FDA in February this year for the treatment of retinoblastoma. If VCN01 is approved by the FDA, orphan drug designation will provide critical market exclusivity, and we plan to take full advantage of the development benefits to which we could be eligible under the Orphan Drug Act, including tax credits, reduced user fees, and again, market exclusivity. We are highly encouraged by the regulatory support for VCN01, which builds on extensive Phase I data across 76 patients, primarily with PDAC and in children with retinal blastoma. We look forward to leveraging our encouraging findings from our Phase I studies in the planned implementation of a controlled Phase II study of intravenous VCN01 in combination with gencytomine and napaxitaxel, the standard of care chemotherapy as a first-line therapy in newly diagnosed patients with metastatic PDAC. We expect to initiate the Phase II study in the fourth quarter of 2022. During the second quarter of 2022, the protocol for the Phase II PDAC clinical trial was submitted to the FDA, as well as Spanish and German regulatory agencies. The proposed trial is designed as a randomized, controlled, multi-center, open-label Phase II study that is expected to enroll up to 92 adults with PDAC at sites in the U.S., Spain, and Germany. The study will have two treatment arms. In arm one, patients will receive gencitabine and napaxitaxel, the standard of care chemotherapy, and in arm two, Patients will receive VCN01 administered seven days prior to gensidamine and napaxitaxel. We are proposing that two doses of VCN01 be administered approximately three months apart. The primary endpoints for the study may include overall survival and safety and tolerability. Additional endpoints may include progression-free survival, objective response rate, and measures of biodistribution, virus replication, and immune response. Since this is anticipated to be a two-arm open-label study, we plan to monitor the study's progress very closely and may try to accelerate the clinical program if supported by the emerging data. The study will be led by Dr. Manuel Hidalgo, an internationally renowned oncologist, scientist, academic, and the chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine, New York Presbyterian Hospital. Now, moving on to the planned study for advanced retinoblastoma. We believe UCN01 holds tremendous promise as an adjunct to intravitreal chemotherapy in patients who fail standard systemic or intra-arterial therapeutic treatments. We are working closely with key opinion leaders from well-known treatment centers in the U.S., Europe, and South America to develop a protocol for a Phase 2-3 study of intravitreal VCN01 to treat vitreous seeds in children with retinoblastoma. There is currently no regulatory guidance for the development of retinoblastoma medicines, so we plan to engage regulatory agencies to determine the appropriate study design and endpoints. We expect to initiate this Phase 2-3 study of VCN01 in the second half of 2023. In addition to the planned company-sponsored studies, there are several investigator-sponsored studies underway exploring the therapeutic potential of VCN01 at world-leading oncology research institutions. In July of 2022, the first patient was dosed and cleared in the safety evaluation period in the University of Pennsylvania's investigator-sponsored open-label, non-randomized Phase I clinical trial evaluating VCN01 in combination with mesothelin-directed lentiviral transduced human chimeric antigen receptor-modified T cells for patients with pancreatic and serious epithelial ovarian cancers. Methothelin is a tumor antigen that is highly expressed in many human cancers, including malignant mesothelioma, pancreatic ovarian, and lung adenocarcinomas. A human chimeric antigen receptor-modified T-cells, or QCART mesome, are autologous T-cells engineered to express an extracellular single-chain variable fragment with methylthelin specificity. The Phase I trial is designed to evaluate the safety and feasibility of this novel combination therapy. We will continue to report on progress of the study as we receive updates. We are also excited about our collaboration with the University of Leeds to evaluate BCN01 in patients with high-grade brain tumors. This study is designed to evaluate whether systemically administered BCN01 could reach tumors in the brain. Treatment of these tumors typically requires surgery and or direct injection. If systemic BCN01 can reach the brain to exert a therapeutic effect, it could potentially transform the way these cancers are treated. The investigator-sponsored study is currently recruiting patients with dosing of the first patient expected in the second half of 2022. In addition to our clinical trials with VCN01, we are keenly advancing our albumin shield technology platform. Albumin shield oncolytic viruses incorporate a preparatory albumin binding domain in the virus's outer shell. This is designed to improve systemic delivery by enabling the virus to coat itself with host serum albumin and prevent inactivation by antiviral neutralizing antibodies. Ideally, this may enable multiple administrations of a systemic OB in traditional therapeutic cycles that could improve treatment outcomes. Preclinical proof of concept for the technology has been demonstrated with VCN11, an albumin shield modified version of VCN01, and we are exploring other albumin shield modified oncolytic viruses with different potential therapeutic payloads. IND-enabling studies are being planned, and we expect to begin these following the completion of ongoing preclinical studies and CMC activities. We look forward to building upon our foundation of compelling proof of mechanism data and continuing to advance our VCN11 program through clinical development. As part of our company's transition to an oncolytic or an oncology focus, we are exploring options to unlock value around our SIN20 and SIN4 assets, which have significant potential opportunity in non-oncology indications. We are currently evaluating the best path forward for these assets and whether to advance these programs internally, out-license, or partner them. In the interim, Washington University continues to screen and enroll patients in our Phase 1b2a clinical study of SYN4 or riboxamase and L-genetic HCT recipients for the prevention of acute graft-versus-host disease in bone marrow transplant patients. The Phase 1b28 study is designed to assess the feasibility of using SYN4 in this specific patient population and to provide key information requested by the FDA regarding the safety and tolerability of SYN4 in patients with impaired intestinal barrier function. Last year, we announced that enrollment in patient dosing had commenced in the first of three sequential antibiotic cohorts that will each be administered a different IV beta-lactam antibiotic to treat fever following conditioning therapy. In total, eight participants in each cohort will receive CIN4 and four will receive placebo. To date, we have dosed 19 patients in the first antibiotic cohort, 12 that are currently considered available. This completes the enrollment requirement for the first cohort, and we expect to report top line data from the first cohort in the second half of 2022. Shortly after, we plan to initiate dosing of the second cohort in the fourth quarter of 2022. In summary, we have made steady progress throughout the second quarter of 2022. With a cash runway into the first quarter of 2024, we are well-positioned to reach potentially transformational inflection points across our impressive pipeline. Near and long-term clinical milestones include the initiation of our Phase 2 study in patients with metastatic PDAC in the fourth quarter of 2022. Top-line data from the first cohort in our Phase 1b2a clinical study of SYN4 and HCT recipients for the prevention of acute graft-versus-host disease in bone marrow transplant patients in the second half of 2022. The data from the VCN01 Phase I investigator-sponsored study in head and neck cancer to be presented at a major medical conference in the third quarter of 2022. Dosing of VCN01 in the first patient with high-grade brain tumors at the University of Leeds in the second half of 2022 The initiation of the second cohort in our Phase 1b2a clinical study of SYN4 for the prevention of acute graft-versus-host disease in bone marrow transplant patients in the fourth quarter of 2022. A planned pre-IND meeting with the FDA for our planned Phase 2-3 study in retinoblastoma by early 2023, and the initiation of our planned Phase 2-3 study in retinoblastoma in the second half of 2023. As you can see, we've positioned our company to deliver on a number of key value-creating milestones over the next 6 to 18 months. By prioritizing our three core clinical programs, VCN01, VCN11, and CIN4, we have the ability to effectively utilize our current cash position, which carries us into the first quarter of 2024, to deliver on important clinical data and related milestones. During the remainder of 2022, we have also planned a number of initiatives to expand our presence with the scientific and investment communities through targeted conferences, outreach, and rebranding activities. We expect to provide more information on our efforts in the months ahead. Before turning to our financial results, I would remind you that the company's common stock began trading on a split-adjusted basis on July 25, 2022. The reverse stock split was affected to ensure we could continue to meet our per share price listing requirements of the NYSE American Stock Exchange. We believe maintaining our listing on the NYSE American is important to the company's performance, corporate visibility, and will provide greater flexibility with respect to future capital market access. On July 29th, With MSD Credit Opportunity Master Fund, we closed the $3 million private placement of 275,000 shares of Series C convertible preferred stock and 100,000 shares of Series D convertible preferred stock. Each share of Series C and Series D preferred stock has a purchase price of $8. Each of these shares are also convertible into shares of the company's common stock at an initial conversion price at $1.22 per share. The proceeds. the SOC offering will further support the advancement of our clinical development programs. The purpose of this financing was twofold. First, the structure of the transaction will aid us administratively during our upcoming shareholder meeting to ensure that we have the necessary quorum for the meeting and the votes needed to help pass key initiatives that we believe are critical to our long-term success and viability. and this is very important, we've added a significant and highly respected institutional investor who is very supportive of the management team, our technologies, and our strategy. Now, I'd like to turn briefly to our financial results for the three months ended June 30, 2022. General administrative expenses increased to $1.5 million for the three months ended June 30, 2022 from $1.3 million for the three months of the June 30, 2021. This increase of 19% primarily comprises of increased consulting and legal costs related to the VCN acquisition, higher insurance costs, audit fees, and public relations expenses, and VCN administrative expenses not included in the prior year. The charge related to stock-based compensation expense was $86,000 to the three months end of June 30, 2022, compared to $83,000 to the three months end of June 30, 2021. Research and development expenses increased to $3.5 million to the three months end of June 30, 2022, from approximately $1.9 million for the three months end of June 30, 2021. This increase of 80% is primarily the result of BCN research expense related to BCN01, not included in the prior year, and to a lesser extent, higher manufacturing expenses for SIN 20, costs incurred related to our Phase 1A clinical trial of SIN 20, and expenses related to our Phase 1B2A clinical trial of SIN 4 and L-genetic HCT recipients. We anticipate research and development expenses to increase as we plan for and initiate enrollment for our Phase 2 clinical trial for BCN01 and PDAC, Phase 2-3 clinical trial in retinoblastoma, expand GMP manufacturing activities for VCN01, and continue with supporting our VCN11 and other preclinical and discovery initiatives. The charge related to stock-based compensation expense was $27,000 for the three months ended June 30, 2022, compared to $19,000 related to stock-based compensation expense for three months ended June 30, 2021. Other income was $17,000 for the three months ended June 30, 2022, compared to other income of $2,000 for the three months end of June 30, 2021. Other income for the three months end of June 30, 2022 is primarily comprised of interest income of $26,000 offset by an exchange loss of $9,000. Other income for the three months end of June 30, 2020 is primarily comprised of interest income. Cash and cash equivalents. totaled $52.3 million as of June 30, 2022, compared to $67.3 million as of December 31, 2021. Our cash and cash equivalents totaled approximately $53.5 million as of August 1, 2022. We believe with an advanced clinical pipeline and strong cash position, we are now well positioned to execute on our priorities despite geopolitical and macroeconomic uncertainty, as well as headwinds in the biotech marketplace. We are more excited than ever about the outlook of the company, and we look forward to providing further updates as we advance our technologies and products. With that, we're happy to take questions.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-